Clinical trial
Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene…
NCT00117650 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00117650 |
|---|---|
| Title | Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication |
| Official title | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-Selection Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 in Patients With Intermittent Claudication |
| Acronym | WALK |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Intermittent Claudication, Peripheral Vascular Disease, Atherosclerosis |
| Intervention type | Biological, Other |
| Interventions | Ad2/HIF-1α/VP16, Saline (Placebo Control) |
| Enrollment | 289 |
| Start date | Feb 1, 2005 |
| Primary completion | Sep 1, 2008 |
| Completion | Mar 1, 2010 |
| First posted | Jul 8, 2005 |
| Last update posted | Apr 3, 2015 |
| Countries | Germany, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: